The tweet was deleted by the author.
But we saved everything 🙂.
Arcturus Therapeutics presented new research on its ARCT-810 mRNA therapy for ornithine transcarbamylase (OTC) deficiency at the SSIEM 2026 conference. The presentation, delivered by Tope Pedro, featured findings on the impact of the therapy on dietary intake and biochemical data in adolescent and adult patients.
This research offers fresh insights into the potential of ARCT-810 as a treatment option for individuals with OTC deficiency, reflecting ongoing advancements in gene-based therapies.
View post on X Loading...